News & Media

    10/17/2017
    Charleston Laboratories, Inc. Resubmits NDA for CL-108 
    08/31/2017
    Charleston Laboratories, Inc. Reacquires Rights to Novel Investigational Treatment CL-108, for Acute Pain and Opioid-Induced Nausea and Vomiting 
    01/26/2017
    Charleston Laboratories, Inc. Announces Formation of U.S. Commercial Subsidiary 
    10/09/2014
    Prescription for Success 
    10/29/2013
    Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain